Compare JBI & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBI | CTMX |
|---|---|---|
| Founded | 2002 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.0M | 977.1M |
| IPO Year | 2021 | 2015 |
| Metric | JBI | CTMX |
|---|---|---|
| Price | $5.45 | $4.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $9.17 | ★ $12.10 |
| AVG Volume (30 Days) | 1.2M | ★ 4.1M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | $9.36 | N/A |
| Revenue Next Year | $3.16 | $7.61 |
| P/E Ratio | ★ $14.30 | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.75 | $0.63 |
| 52 Week High | $10.80 | $8.21 |
| Indicator | JBI | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 48.77 | 43.12 |
| Support Level | $5.17 | $4.02 |
| Resistance Level | $5.68 | $4.72 |
| Average True Range (ATR) | 0.21 | 0.28 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 39.26 | 17.94 |
Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. The company provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.